1. Introduction {#sec1}
===============

Tetracyclines (TCs) are characterized by the tetracyclic naphthacene core and could inhibit protein synthesis by binding the 30S ribosomal subunit \[[@bib1],[@bib2]\]. Tolerance of chemical modifications on ring C and ring D in TC contributed to the successful synthesis of the second and third generations of TCs with enhanced antibiotic activity and pharmacological properties, such as doxycycline, minocycline, tigecycline and omadacycline \[[@bib1]\]. Minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracycline) ([Fig. 1](#fig1){ref-type="fig"}A) is one of the second-generation TCs, and possesses attractive advantages such as better absorption, longer half-life and almost complete bioavailability \[[@bib3], [@bib4], [@bib5], [@bib6]\]. It is used for the treatment of acne vulgaris and some sexually transmitted diseases, and it also exhibits multiple non-antibiotic activities including anti-inflamation, anti-autoimmune disorders and neuroprotection \[[@bib7], [@bib8], [@bib9]\]. Tigecycline (9-*t*-butylglycylamido-minocycline) ([Fig. 1](#fig1){ref-type="fig"}A) is the first glycylcycline derived from minocycline, and it was also referred to as one of the third-generation TCs \[[@bib10]\]. It can overcome most of the currently known tetracycline resistance mechanisms, especially efflux pumps and ribosomal protection \[[@bib11],[@bib12]\]. Thus, it showed notable activity against methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci (VRE), and penicillin-resistant *Streptococcus pneumonia* (PRSP) \[[@bib13]\]. Because of its prominent antibacterial effect, tigecycline was approved by FDA for the treatment of complicated skin and skin structure infections (cSSSIs) as well as complicated intra-abdominal infections (cIAIs) in 2005 \[[@bib14],[@bib15]\].Fig. 1Representative chemical structures and CTC biosynthetic pathway. (A) Chemical structures of minocycline and tigecycline. (B) The deduced biosynthetic pathway of CTC based on previous studies of OTC. Significant intermediates during the synthetic process are shown. Chemical structures of DMTC and DMCTC accumulated in *ΔctcK* mutant strain are highlighted in the dotted rectangular box.Fig. 1

Demecycline (DMTC) and demeclocycline (DMCTC) ([Fig. 1](#fig1){ref-type="fig"}B) can be reduced to sancycline (6-demethyl-6-deoxytetracycline), the minimum structure necessary for antimicrobial activity, and then converted to 7-aminosancycline or minocycline \[[@bib4],[@bib16]\]. The achievable transformation from DMTC and DMCTC to minocycline and tigecycline made them important drug precursors. Total chemical synthesis of DMTC and DMCTC is a time-consuming and high-cost process \[[@bib17]\], so high-efficient biosynthesis is still required, which in turn calls for detailed illustration on the biosynthesis machinery. To date, TCs such as chlortetracycline (CTC) \[[@bib18]\], tetracycline (TC) \[[@bib19]\] ([Fig. 1](#fig1){ref-type="fig"}B) and oxytetracycline (OTC) \[[@bib20]\] have been found to be produced by many *Streptomyces*. Moreover, microbial productivities of natural TCs have been dramatically improved, benefiting from random mutagenesis in combination with optimization of fermentation conditions \[[@bib21],[@bib22]\], metabolic engineering approaches \[[@bib23], [@bib24], [@bib25]\] and genetic manipulation of regulatory genes \[[@bib26],[@bib27]\]. All these efforts set important stage for engineering construction of DMTC and DMCTC high-yielding strains. In fact, during the study of the CTC-producing strain *S. aureofaciens*, several attempts have been made to produce DMTC and DMCTC by adding certain C-methylation inhibitors to the fermentation broth \[[@bib28], [@bib29], [@bib30]\], screening for DMTC- and DMCTC-accumulating spontaneous or induced random mutants \[[@bib31],[@bib32]\], and introducing site specific mutation via DNA recombination to eliminate activity of tentative enzymes responsible for C6-methylation \[[@bib33],[@bib34]\]. But these methods seemed to be costly and labor-intensive without sufficient understanding of CTC biosynthetic pathway. So, the detailed biosynthetic mechanism of DMTC and DMCTC still await discovery.

In 2013, our group successfully cloned *ctc* gene cluster in the CTC high-yielding industrial strain *S. aureofaciens* F3. Based on bioinformatics analysis, genetic manipulation and biochemical characterization of the halogenase CtcP \[[@bib35]\], we have proposed a biosynthetic pathway of CTC ([Fig. 1](#fig1){ref-type="fig"}B). Pretetramid, the precursor of DMTC and DMCTC, was speculated to be involved in CTC biosynthesis, and the successful transformation of TC to CTC catalyzed by CtcP opened up the possibility that DMCTC might be transformed from DMTC \[[@bib35],[@bib36]\]. Meanwhile, the structural difference between TC and DMTC, CTC and DMCTC suggested that a methyltransferase might participate in the introduction of C6-methyl. In this study, we demonstrated the function of C-methyltransferase gene *ctcK* in *ctc* cluster. By genetic interruption of *ctcK*, we successfully obtained the DMTC- and DMCTC-producing strain. Moreover, through metabolic engineering optimization of the *ΔctcK* mutant strain, we developed a more productive producer of DMCTC. With further engineering manipulation in future, these two strains reported here could be potential strains providing synthetic precursors for semisynthesis of minocycline, tigecycline and other novel tetracycline derivatives.

2. Materials and methods {#sec2}
========================

2.1. Bacterial strains, plasmids, and general techniques {#sec2.1}
--------------------------------------------------------

Strains and plasmids used in this study are listed in [Table 1](#tbl1){ref-type="table"}. *S. aureofaciens* F3, the CTC high-yielding industrial strain, was used as the original strain for construction of *ΔctcK* mutant and then the *ctcK* complementary strain. F3:3*ctcP* \[[@bib35]\], the *ctcP* overexpression mutant, was used for *ctcK* inactivation to increase CTC yield. *Escherichia coli* BW25113/pKD46, DH10B and ET12567/pUZ8002 were used for gene replacement based on λ-Red-recombination, gene cloning and intergeneric conjugation between *E. coli* and *S. aureofaciens* F3 \[[@bib37],[@bib38]\], respectively. *E. coli* BL21 Gold (DE3) was used as the host for heterologous protein expression and pET28a was the expression vector. pIJ778 \[[@bib37],[@bib38]\] was used as the template for amplification of an *aadA* + *oriT* cassette for *ctcK* disruption. pPM927 \[[@bib39]\], an integrating vector, was used for *ctcK* complementation and pJTU968 \[[@bib40]\] was a transition vector for addition of *permE\** before *ctcK* gene. General genetic manipulations of *E. coli* or *Streptomyces* were carried out according to reported procedures \[[@bib41],[@bib42]\].Table 1Strains and plasmids used in this study.Table 1Strain or plasmidDescriptionSource/Reference***Streptomyces* strains***S. aureofaciens* F3Industrial strain producing CTCJinhe biotech. Lt.*ΔctcKS. aureofaciens* F3 mutant with a 672 bp fragment of *ctcK* substituted by *aadA + oriT* cassetteThis study*ΔctcK*::*ctcKctcK* complementary strainThis studyF3::3*ctcP*ZT09, *ctcP* quadrupled with three extra copies through integrative vector\[[@bib35]\]3*ctcPΔctcK*ZT09 mutant with *ctcK* disruptionThis study***E. coli* strains**BW25113/pKD46*E. coli* K-12 derivative: *ΔaraBAD Δ*rhaBAD/*ori*R101 *repA*101 ts*P*~ara~B^−^*gam*^−^*bet*^-^*exo bla*\[[@bib37],[@bib38]\]DH10BF^−^*mcrA* Δ(*mrr*^*-*^*hsdRMS*^-^*mcrBC*)*ϕ80*d *lacZ ΔM15 ΔlacX74 deoR recA1 endA1 ara Δ139 D* (*ara,leu*)*1697 galU galK λ*^*-*^*rspL nupG*GibcoBRLET12567/pUZ8002*dam dcm hsd*S/pUZ8002\[[@bib47]\]BL21Gold (DE3)F^−^*ompT hsdS*~*B*~(*r*~*B*~^*-*^*m*~*B*~^*-*^) *gal dcm* (DE3) pLysS (Cm^R^)Strategene**Plasmids**17G4pCC1FOS derivative with the whole *ctc* gene cluster\[[@bib35]\]pIJ778*aadA*, *oriT*\[[@bib37],[@bib38]\]pET28aKan^R^, pBR322 origin, PT7NovagenpJTU968pRSETb derivative, *bla*, *permE\**\[[@bib40]\]pPM927*tsr*, *oriT*, *int*, *attP*\[[@bib39]\]pYWN0117G4 derivative in which *ctcK* was substituted by *aadA* + *oriT* cassette using PCR-targeting recombinationThis studypYWN02pET28a derivative with a PCR fragment harboring *ctcK* amplified from *S. aureofaciens* F3 genome and inserted by one-step cloningThis studypYWN03pJTU968 derivative with insertion of *Nde*I-*Eco*RI double-digested fragment harboring *ctcK* from pYWN02This studypYWN04pPM927 derivative with insertion of *Mun*I-*Eco*RI double-digested fragment harboring *permE*\* and *ctcK* from pYWN03This study

*S. aureofaciens* F3 and its derivative strains were cultured at 30 °C on solid YM medium (34% oat flour, 16% agar, 0.005% MgSO~4~, 0.010% KH~2~PO~4~ and 0.015% (NH~4~)~2~HPO~4~) for sporulation, and SFM medium (2% mannitol, 2% soya flour and 2% agar) was used for conjugation. The seed liquid medium was TSBY (0.5% yeast extract, 3% tryptone soya broth, 10.3% sucrose) and the fermentation medium per liter contained 80.0 g corn starch, 40.0 g soya flour, 1.0 g yeast extract, 14.0 g tryptone, 8.0 g corn milk, 7.0 g CaCO~3~, 3.5 g (NH4)~2~SO~4~, 2.5 g NaCl, 0.25 g MgSO~4~ and 15 ml soya bean oil. *E. coli* strains were cultivated at 37 °C in LB liquid medium or on LB agar plate.

2.2. Bioinformatics analysis {#sec2.2}
----------------------------

Homologous proteins of CtcK were identified by online software NCBI Blastp (<https://blast.ncbi.nlm.nih.gov/>). Multiple sequence alignment was conducted using BioEdit software and the referred homologous proteins were ChdMI (AHD25937.1) from *Amycolatopsis sulphurea*, OxyF (AAZ78330.1) from *Streptomyces rimosus*, DacM1 (AFU65900.1) from *Dactylosporangium* sp. SC14051, BchU (WP_010931722.1) from *Chlorobaculum tepidum* and LaPhzM (AMQ09360.2) from *Lysobacter antibioticus* OH13. The prediction of CtcK\'s secondary structure was conducted by PredictProtein (<https://www.predictprotein.org/>) \[[@bib43]\] and PSIPRED 4.0 (<http://bioinf.cs.ucl.ac.uk/psipred/>) \[[@bib44],[@bib45]\].

2.3. Construction of gene inactivation and complementation mutants {#sec2.3}
------------------------------------------------------------------

The primers used in this study are listed in [Table 2](#tbl2){ref-type="table"}. Fosmid 17G4 was first introduced into *E. coli* BW25113 by electroporation. Plasmid pIJ778 was used as the template for PCR amplification of *aadA* + *oriT* cassette with primers KTAR-P1 and KTAR-P2. Then 672 bp fragment of *ctcK* was replaced by the spectinomycin resistant cassette on 17G4 using PCR-targeting strategy with the help of inducible λ-Red recombinase \[[@bib37]\]. After PCR verification and replication in *E. coli* DH10B, the mutant plasmid pYWN01 was finally introduced into *S. aureofaciens* F3 by conjugation between *E. coli* ET12567/pUZ8002 and *Streptomyces*. The potential double-crossover *ΔctcK* strains were firstly obtained from antibiotic selection (spectinomycin 50 μg/ml and nalidixic acid 50 μg/ml) on SFM medium and then incubated on YM medium with the same antibiotics. The positive *ΔctcK* strains were verified by PCR using primers KYZ-P1 and KYZ-P2.Table 2Primers used in this study.Table 2PrimerSequence (5′-3′)UseKTAR-P1GGCTGACGCCCTGGGCGAGGAGCCGGCCGGCGCGGCCGAATTCCGGGGATCCGTCGACCAmplification of *aadA* + *oriT* cassette from pIJ778KTAR-P2CTGCCGTCCACCAGGTTCTCGACCACGATCACCCGGCTGTGTAGGCTGGAGCTGCTTCKYZ-P1ACGGACGCCTCGGTGTACGTGVerification of *ΔctcK* mutant strainKYZ-P2CATCTGACCCCGCTCCCCTTCKEXP-P1TGCCGCGCGGCAGC[CATATG]{.ul}ATGACGGACAACGGCGAGATC (*Nde*I site)Amplification of *ctcK* fragment for insertion into pET28a by one-step cloningKEXP-P2TGTCGACGGAGCTC[GAATTC]{.ul}TCAGCCCCGTTCGGGCACCAC (*Eco*RI site)927YZ-P1CCCGATGCTAGTCGCGGTTGATCVerification of *ctcK* complementary strain927YZ-P2CGTCGTCCCACTCCAGGATGTTCTT

As for *ctcK* complementation, pJTU968-derived plasmid pYWN03 was first constructed by insertion of the complete *ctcK* gene behind *permE\** promoter. Then the *permE\**+*ctcK* fragment was double-digested from PCR-confirmed pYWN03 by *Mun*I-*Eco*RI and transferred to *Eco*RI-digested integrating vector pPM927. The derivative plasmid pYWN04 was introduced into *ΔctcK* mutant strain by conjugation and positive mutants were firstly selected with spectinomycin and thiostrepton and then verified by PCR using primers 927YZ-P1 and 927YZ-P2.

2.4. Fermentation, isolation and analysis of TCs {#sec2.4}
------------------------------------------------

Spores stored in 20% glycerol were inoculated in TSBY medium in the proportion of 0.1% and cultivated at 30 °C for about 24 h. Then 5 ml seed broth was transferred to 100 ml fermentation medium for another 5 days. As for quantitative fermentation, 1 ml culture was collected and ten times diluted by TSBY medium to monitor its OD~450~. The transferred volumes were calculated according to it to ensure equal amount of seeds were inoculated in fermentation medium. Proper antibiotics were added in the seed medium when mutant spores were used, and all cultivation procedures were performed in flasks containing coil springs.

After fermentation, pH of the broth was adjusted to 1.5--2.0 with oxalic acid to release products from cells. The lysate mixture was centrifuged and the supernatant was filtrated with 0.22 μm polyether sulfone (PES) membrane. High-performance liquid chromatography (HPLC) was performed on an Agilent HPLC series 1100 system with an Agilent TC-C18 (2) column (5 μm, 4.6 × 250 mm). Separation of different fermentation products was achieved under a constant flow rate of 0.6 ml/min with 80% buffer A (contained 0.2% formic acid) and 20% buffer B (acetonitrile). All TCs were monitored at 360 nm and DMCTC was quantified on the basis of peak areas from the standard curve established using DMCTC standard. For high-resolution mass measurements, an Agilent 1200 series LC/MSD trap system in tandem with a 6530 Accurate-Mass quadrupole time-of-flight (Q-TOF) mass spectrometer was used with an electrospray ionization source (100--1000 *m*/*z* mass range, positive mode).

2.5. Time-course analysis of fermentation products in S. aureofaciens mutant {#sec2.5}
----------------------------------------------------------------------------

For time-course analysis of fermentation products, 5 ml fermentation broth was removed from the same shake flask every 24 h from Day 2 to Day 5 and stored at 4 °C for extraction. Since soya bean oil was added in the fermentation medium, the supernatant of acidified culture broth could not be directly concentrated. Therefore, equal volume of *n*-hexane was used to extract oil out of the broth at room temperature. After extraction of 3--5 times, the remaining broth was freeze-dehydrated in vacuum and the resultant products were dissolved in 100 μl water for HPLC analysis.

2.6. Detection of spontaneous transformation of DMTC and DMCTC {#sec2.6}
--------------------------------------------------------------

To explore the spontaneous transformation of DMTC and DMCTC, DMTC and DMCTC standards (4*S* configuration) were diluted to 200 μM and 100 μM respectively, which were close to their concentrations in *ΔctcK* fermentation broth. Then 100 μl *ΔctcK* fermentation broth and diluted standards were all half divided and one part was kept at room temperature while the other was stored under −30 °C. After 5 days, all samples were analyzed by HPLC.

2.7. Heterologous expression and purification of recombinant CtcK {#sec2.7}
-----------------------------------------------------------------

The complete coding DNA sequence (CDS) flanked by two 20 bp homologous arms was first amplified from the genomic DNA of *S. aureofaciens* F3 using primers KEXP-P1 and KEXP-P2. The two homologous arms respectively carried upstream region including *Nde*I site as well as downstream region including *Eco*RI site of pET28a. Then the specific PCR product was inserted into *Nde*I-*Eco*RI double-digested pET28a plasmid using the Ezmax one-step cloning kit (Tolo Biotech, China), generating recombinant *ctcK* expression vector pYWN02. After confirmation by DNA sequencing, pYWN02 was transformed into *E. coli* BL21Gold (DE3). The resulted transformant was cultured in LB medium containing 50 μg/ml kanamycin at 37 °C until OD~600~ reached 0.6, and isopropylthio-β-[d]{.smallcaps}-galactoside (IPTG) at a final concentration 0.2 mM was added to induce protein expression. The cells were further cultivated at 30 °C for 6 h and harvested by centrifugation (3500 rpm, 15 min, 4 °C) and resuspension in 20 ml of buffer A (50 mM Tris-HCl, 300 mM NaCl, pH 8.0).

For purification of the His~6~-tagged protein, bacterial cells were lysed by high pressure cracker at 600 bar, then cellular debris was removed by centrifugation (9000 rpm, 1 h). The supernatant filtrated with 0.45 μm PES membrane was loaded on nickel-affinity chromatography to purify CtcK using standard protocols. Eluted with increasing gradient of buffer B (buffer A with 500 mM imidazole), purified protein was concentrated with centrifugal filters (Amicon) and desalted by gel filtration chromatography. Final concentration of the protein was determined with Bradford assay using bull serum albumin (BSA) as a standard, and the protein was stored at −80 °C in buffer A with 10% glycerol.

2.8. In vitro enzymatic reactions of CtcK {#sec2.8}
-----------------------------------------

CtcK was purified to homogeneity. 10 mM DMCTC hydrochloride (USP Reference Standard) was dissolved in water and 10 mM DMTC (CATO Research Chemicals Inc.) was dissolved in 0.1 M hydrochloric acid as stock. Methylation reactions were conducted in the typical 100 μl system previously reported \[[@bib46]\] which consisted of 1 mM S-adenosylmethionine (SAM, New England Biolabs Inc.), 1 mM DMTC or DMCTC, and 50 μM methyltransferase CtcK in PBS buffer (10 mM Na~2~HPO~4~, 1.75 mM KH~2~PO~4~, 137 mM NaCl, 2.65 mM KCl, pH 7.6). Boiled CtcK was used as negative control and 2 mM MgSO~4~ was added in the "+Mg^2+^" system to confirm whether it could facilitate methylation reaction. All reactions were started by incubation under 30 °C for 12 h. The reactions were quenched by the addition of 100 μl water and 100 μl chloroform. Then the mixtures were vortexed and centrifuged to remove the precipitated protein. The supernatants were vacuum freeze-dehydrated and dissolved in 40 μl water before subjected to HPLC analysis.

3. Results {#sec3}
==========

3.1. The ctc gene cluster encoded a C-methyltransferase CtcK {#sec3.1}
------------------------------------------------------------

According to previous bioinformatics analysis, two possible methyltransferases CtcO and CtcK were encoded in the *ctc* gene cluster. CtcO is deduced to be a N-methyltransferase possessing 52% identity with OxyT, which catalyzes a *N, N*-dimethylation reaction to yield anhydrotetracycline (ATC) \[[@bib48]\]. CtcK showed 69% sequence identity with the C-methyltransferase OxyF, which is responsible for C-methylation of pretetramid to produce 6-methylpretetramid during OTC biosynthesis \[[@bib49]\]. Meanwhile, it exhibited homology with other C-methyltransferases involved in natural product biosynthesis, such as ChdMI (67% identity) from chelocardin-producing strain *Amycolatopsis sulphurea* \[[@bib50]\] and DacM1 (66% identity) from dactylocycline-producing strain *Dactylosporangium* sp. SC 14051 \[[@bib51]\]. On the other hand, based on the NCBI Blastp analysis, a conserved protein domain corresponding to C20-methyltransferase BchU (identity 23%, PDB code: [1X19](pdb:1X19){#intref0025}) was identified. BchU was reported to methylate cyclic tetrapyrrole chlorin in the bacteriochlorophyll *c* production pathway in photosynthetic green sulfur bacteria *Chlorobaculum tepidum* \[[@bib52]\]. To consolidate the finding of CtcK as a C-methyltransferase, the possible secondary structure of it was predicted using PredictProtein and PSIPRED 4.0. The predicted secondary structure possessed a Rossmann-like superfold containing alternating α-helixes and β-strands ([Fig. 2](#fig2){ref-type="fig"}), which was similar to LaPhzM (identity 33%, PDB code: [6C5B](pdb:6C5B){#intref0030}) from *Lysobacter antibioticus* OH13, an O-methyltransferase participating in myxin biosynthesis \[[@bib53]\], and is also a typical feature of Class I methyltransferases \[[@bib54]\]. Furthermore, multiple sequence alignment of CtcK and these homologous proteins confirmed the existence of a common glycine-rich SAM-binding motif \[[@bib54]\], which was marked by a rectangle in [Fig. 2](#fig2){ref-type="fig"}. Taken together, CtcK is probably a SAM-dependent Class I C-methyltransferase.Fig. 2Sequence alignment of CtcK with other homologous methyltransferases. Residues conserved among them are highlighted in grey. The glycine-rich SAM-binding motif is marked with a rectangular box. The secondary structure was predicted using PredictProtein \[[@bib43]\] and PSIPRED 4.0 \[[@bib44],[@bib45]\]. α-Helixes and β-strands are indicated by cylinders and arrows, respectively.Fig. 2

3.2. ΔctcK strain accumulated DMTC and DMCTC {#sec3.2}
--------------------------------------------

Based on the bioinformatics analysis of CtcK as a possible C-methyltransferase, it might be responsible for methylation of C6 in CTC biosynthesis. The absence of the methyl group in DMTC and DMCTC might be attributed to the inactivity of CtcK. In order to verify our hypothesis, 672 bp of *ctcK* was replaced by a spectinomycin resistant gene in *S. aureofaciens* F3 genome through homologous recombination ([Fig. 3](#fig3){ref-type="fig"}A and B). The *ΔctcK* mutant abolished the production of TC and CTC, but accumulated two new compounds **1** and **2** ([Fig. 3](#fig3){ref-type="fig"}C). The retention time and UV absorption spectra of these two compounds were identical with that of DMTC and DMCTC, respectively ([Fig. 3](#fig3){ref-type="fig"}C and D). Further Q-TOF mass spectrometry analysis of **1** and **2** gave molecular ion peaks at *m*/*z* 431.1228 (\[M+H\]^+^) and 465.0734 (\[M+H\]^+^), which were also consistent with that of DMTC and DMCTC ([Fig. 3](#fig3){ref-type="fig"}E). To validate that the production of DMTC and DMCTC were solely due to inactivation of *ctcK*, a copy of *ctcK* on the plasmid pYWN04 under the control of *permE*\* promoter was introduced into the *ΔctcK* strain. As can be seen in [Fig. 3](#fig3){ref-type="fig"}C, the resulted *ctcK* complementary strain recovered TC and CTC production. All results above led to the conclusion that DMTC and DMCTC can be produced by inactivation of the C-methyltransferase gene *ctcK*.Fig. 3Construction and fermentation product analysis of the *ΔctcK* mutant strain. (A) The schematic construction of *ctcK* disrupted strain. The 672 bp fragment of *ctcK* was replaced by an *oriT + aadA* cassette through fosmid-based homologous recombination. (B) PCR confirmation of *ctcK* gene replacement. Lane 1--6, the *ΔctcK* mutant, in which the mutants give the expected 2.1 kb PCR products. *S. aureofaciens* F3 (F3) produced 1.4 kb products. (C) HPLC profiles of fermentation products of *ΔctcK*, *ΔctcK*:*ctcK* and F3 strains. Compounds **1** and **2** are new products accumulated in *ΔctcK* mutant strain. (D)The UV spectra of compounds **1** and **2** contrasted with DMTC and DMCTC standards respectively. (E) Q-TOF analysis of compounds **1** and **2**.Fig. 3

However, based on the previous study of OTC biosynthesis \[[@bib36]\], the *ΔctcK* mutant strain should accumulate pretetramid rather than DMTC and DMCTC ([Fig. 3](#fig3){ref-type="fig"}). The accumulation of DMTC and DMCTC might result from transformation of intermediates without the C6 methyl by downstream enzymes. To catch pretetramid and any other possible intermediates, we next conducted time-course analysis of the fermentation products in the *ΔctcK* strain by HPLC. 5 ml fermentation broth was sampled from the same shake flask at the same time point from Day 2 to Day 5. Data depicted in [Fig. 4](#fig4){ref-type="fig"}A showed that the production of DMTC and DMCTC continuously increased. However, no new product was detected except for two additional peaks with close retention time and identical UV spectra to that of DMTC and DMCTC ([Fig. 4](#fig4){ref-type="fig"}A). Inspired by the spontaneous transformation of 4*S*-CTC and 4*S*-TC to their 4*R* epimers at room temperature \[[@bib35]\], we wondered whether the two additional peaks were spontaneous transformed DMTC and DMCTC with another configuration. To verify the possibility, DMTC and DMCTC standards (4*S* configuration) as well as unconcentrated sample collected at Day 5 in time-course fermentation process was divided into two equal parts respectively, and each part was kept at room temperature or −30 °C for 5 days. The HPLC profile in [Fig. 4](#fig4){ref-type="fig"}B showed that compared to samples kept at −30 °C, 4*S*-DMTC and 4*S*-DMCTC were both reduced at room temperature, but two peaks at 9 min and 13 min obviously rose. These two peaks in *ΔctcK* fermentation sample not only had identical retention time with risen peaks detected in DMTC and DMCTC standards, but also showed *m*/*z* values corresponding to DMTC and DMCTC in Q-TOF analysis ([Fig. 4](#fig4){ref-type="fig"}B). Since DMTC and DMCTC standards have been NMR-characterized by their suppliers to be mixed with a small amount of 4*R* epimers, the above results confirmed that these two peaks were spontaneously transformed 4*R* epimers during the concentration process at room temperature.Fig. 4Time-course fermentation and thermal stability of DMTC and DMCTC. (A) HPLC profiles of time-course fermentation products of *ΔctcK* mutant strain to catch possible intermediates. Samples were removed from the same shake flask every 24 h from Day 2 to Day 5. (B) Spontaneous transformation of 4*S*-DMTC and 4*S*-DMCTC to their 4*R* epimers at room temperature (the red line) in standard DMTC, DMCTC and *ΔctcK* fermentation sample. The same samples stored at −30 °C (the blue line) for the same amount of time (5 days) were also analyzed for comparison. The *m*/*z* values of spontaneously transformed 4*R* epimers determined by Q-TOF mass spectrometry are shown in the rounded rectangle boxes.Fig. 4

The time-course analysis of fermentation products in *ΔctcK* strain did not reveal the accumulation of the proposed substrate of CtcK. Meanwhile, no biosynthetic intermediate for downstream tailoring enzymes has been found. These data suggested that the production of DMTC and DMCTC could be attributed to the relaxed specificity of downstream enzymes. However, the possibility that CtcK might catalyze the direct methylation of DMTC and DMCTC to TC and CTC could not be excluded.

3.3. Heterologous expression and *in vitro* enzymatic assay of CtcK {#sec3.3}
-------------------------------------------------------------------

Without the pretetramid at hand, we tried testing whether CtcK could catalyze the direct methylation of DMTC and DMCTC. Firstly, the *ctcK* gene was cloned and expressed in *E*. *coli* BL21Gold (DE3) as a N-His~6~ recombinant protein. Then the CtcK protein was purified by nickel-affinity chromatography. The purity and size (39.2 kDa) of the protein were examined by 15% SDS-PAGE ([Fig. 5](#fig5){ref-type="fig"}A). Referring to the typical methyltransferase reaction system \[[@bib46]\], the reaction was conducted in PBS buffer and SAM was selected as methyl group donor. Unexpectedly, no CTC or TC was generated in the reaction systems even when they were incubated overnight at 30 °C ([Fig. 5](#fig5){ref-type="fig"}B and C). And addition of MgSO~4~ led to the occurrence of precipitation, which was possibly because of the chelation between magnesium ion and TCs \[[@bib55]\]. It was reported that OxyF, the homologous protein of CtcK, possessed high specificity toward its natural substrates \[[@bib49]\], thus the nonreactivity of CtcK on DMTC and DMCTC suggested its strict substrate specificity. In other words, the substrate of CtcK might be an early biosynthetic intermediate involved in CTC biosynthesis.Fig. 5Characterization of the purified CtcK and its *in vitro* enzymatic assay. (A) SDS-PAGE analysis of the purified His~6~-CtcK (M~r~ = 39.2 kDa). (B) HPLC profiles of CtcK incubated with DMTC in the presence (i) or absence (ii) of Mg^2+^. The boiled CtcK incubated with DMTC (iii) was used as negative control. iv and v are DMTC and TC standards. (C) HPLC profiles of CtcK incubated with DMCTC in the presence (i) or absence (ii) of Mg^2+^. The boiled CtcK incubated with DMCTC (iii) was used as negative control. iv and v are DMCTC and CTC standards.Fig. 5

3.4. Construction of high DMCTC production strain {#sec3.4}
-------------------------------------------------

CtcP is the halogenase that catalyzes the last step, conversion of TC to CTC, in CTC biosynthetic pathway \[[@bib35]\]. To enhance its catalytic efficiency, 1--5 copies of *ctcP* was respectively introduced into the F3 strain under the control of constitutive *permE\** promoter. Consequently, the integration of three extra copies of *ctcP* (ie, F3:3*ctcP*) could most effectively improve CTC production by 73% in *S. aureofaciens* F3 \[[@bib35]\], which implied that the accumulation of DMCTC might also be increased by similar manipulation of *ctcP*. Based on previous studies, we constructed the engineering strain through inactivation of *ctcK* in the F3:3*ctcP* mutant strain ([Fig. 6](#fig6){ref-type="fig"}A). As can be seen from [Fig. 6](#fig6){ref-type="fig"}B, overexpression of *ctcP* in the *ΔctcK* strain contributed to the increased production of DMCTC. After quantitative analysis, the yield of DMCTC increased 31%, reaching up to 21.6 mg/L. The successful construction of the strain with high DMCTC production set important stage for future yield optimization by metabolic engineering.Fig. 6Construction and DMCTC yield analysis of the 3*ctcPΔctcK* engineering strain. (A) PCR confirmation of *ctcK* gene replacement in F3:3*ctcP*. Lane 2 and 4, engineering strains with successful *ctcK* disruption. (B) Quantitative analysis of DMCTC yield in strains 3*ctcPΔctcK*-2, 3*ctcPΔctcK*-4 and *ΔctcK.* The productivity of DMCTC in *ΔctcK* is determined as 1 for comparison and quantitative fermentation was performed in three replicates.Fig. 6

4. Discussion {#sec4}
=============

Minocycline and tigecycline ([Fig. 1](#fig1){ref-type="fig"}A) are both TCs extensively used in clinical with remarkable potency. Minocycline exhibits a broad antibiotic spectrum including activity against some tetracycline-resistant staphylococci \[[@bib56]\], and various non-antibiotic effects of it further extend the field of its application \[[@bib7]\]. Tigecycline is referred to as the last line of defense against multidrug-resistant bacteria because it can conquer most of antibiotic resistance mechanisms known in them by virtue of its long glycyl side chain and high binding affinity \[[@bib56],[@bib57]\]. Currently, a prevalent strategy for production of non-natural tetracycline derivatives is semisynthesis, which means chemical synthesis of final products using natural products as raw materials. As for minocycline and tigecycline, their semisynthetic precursors are microbially synthesized DMTC and DMCTC \[[@bib4],[@bib10]\].

DMTC and DMCTC are C6-demethylated derivatives of TC and CTC, respectively. Both TC and CTC are produced by *S. aureofaciens*, and the biosynthetic studies have been conducted through random mutation and feeding experiments \[[@bib58]\]. Induced mutations during this process coincidently generated DMTC- and DMCTC-yielding strains \[[@bib31],[@bib59]\], but how their genetic and physiological characteristics were varied remained unknown. In order to facilitate directed metabolic engineering of *S. aureofaciens* strains for DMTC and DMCTC production, it is necessary to discuss the biosynthetic mechanism of CTC.

During previous study of CTC in *S. aureofaciens* F3, the complete *ctc* gene cluster has been cloned \[[@bib35]\], and the biosynthetic pathway ([Fig. 1](#fig1){ref-type="fig"}B) was speculated based on OTC\'s \[[@bib36]\] owing to the high homology of genes involved in these two clusters. Also, the halogenase CtcP was characterized to be responsible for the transformation of TC to CTC by gene inactivation and overexpression. But the function of CtcK was just predicted according to that of its homologous protein OxyF and hasn\'t been specifically determined.

In this study, we first conducted multiple sequence alignment of CtcK and its homologous proteins, which indicated the conserved SAM-binding motif. Subsequent prediction of its secondary structure revealed typical Rossmann-like superfold of Class I methyltransferases. Disruption of *ctcK* resulted in the accumulation of two new products DMTC and DMCTC, which were confirmed by HPLC and Q-TOF analysis. The absence of 6-methyl suggested the role of CtcK in the methylation of C6. However, the predicted substrate pretetramid of CtcK was not accumulated during the time-course analysis of fermentation products in *ΔctcK* mutant, while two detected risen peaks were verified by Q-TOF as 4*R*-DMTC and 4*R*-DMCTC resulting from the spontaneous transformation of 4*S*-DMTC and 4*S*-DMCTC, respectively. The production of DMTC and DMCTC in *ΔctcK* mutant was then attributed to the substrate tolerance of downstream modification enzymes involved in CTC biosynthesis. Consistently, DMTC and DMCTC could not be methylated into TC and CTC in the *in vitro* enzymatic assay of CtcK. This data supported the proposal that CtcK functions at the middle stage of CTC biosynthetic pathway, rather than catalyzes the direct methylation of DMTC and DMCTC into TC and CTC. The attempt to inactivate *ctcK* in overexpression strain of the halogenase CtcP successfully improved DMCTC yield, suggesting the feasibility of rational metabolic engineering to obtain expected products.

However, although overexpression of CtcP in the F3:3*ctcP* mutant strain \[[@bib35]\] could drive the transformation of DMTC to DMCTC, a certain amount of DMTC still existed in the fermentation broth probably because of the low halogenation efficiency when the substrate was DMTC rather than TC. As is shown in halogenase engineering studies on tryptophan halogenases RebH and SttH \[[@bib60], [@bib61], [@bib62]\], structure-based point mutations and directed evolution could broaden the substrate scope thereby improve the reactivity of them \[[@bib63]\], which might be practicable ways to provide CtcP with more flexible substrate selectivity. In addition, overexpressing positive regulatory genes or inactivating repressors, increasing intracellular precursor supply and manipulating resistance genes in *ctc* cluster are also potentially useful for DMCTC overproduction to meet commercial needs \[[@bib64]\].

On the other hand, the structures of naturally-occurring compounds isolated from the strains lag far behind in terms of structural diversity. Although derivatives with different structural moieties have been isolated by mutating biosynthetic genes, the number and the productivities were limited and this is still the bottleneck of industrial production of new TC derivatives \[[@bib21],[@bib22],[@bib31],[@bib32]\]. Fortunately, with the advancement in the field of synthetic biology together with genome sequencing and genome mining techniques, the limitation of biological synthesis could be broken and natural metabolic pathways could be diversified to generate non-natural products possessing novel activities \[[@bib65],[@bib66]\]. So, it\'s a more extensive application prospect of DMTC and DMCTC if they can be produced as intermediates in reprogrammed biosynthetic pathways employing heterologous or engineered enzymes to construct more TC derivative antibiotics.

In summary, the detailed functional investigation of the C-methyltransferase CtcK expanded the understanding of CTC biosynthesis. Moreover, an engineering strain that can produce DMTC and DMCTC was successfully conducted by inactivation of *ctcK*. Then yield of DMCTC was improved with the help of three extra copies of the halogenase gene *ctcP*. Compared to random mutation, the direct manipulation of *ctcK* reported here is a more time-saving and convenient way to achieve the biosynthesis of DMTC and DMCTC. Meanwhile, the genetic manipulation of genes within *ctc* cluster doesn\'t alter the whole genetic background of the strain, which can facilitate subsequent metabolic engineering or other manipulations to construct more productive strains or produce novel TC derivatives.
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